Abstract: Disclosed are a system and method for reliquefaction of boil-off gas of a ship and a system and method for treating off-gas of a reliquefaction apparatus. The boil-off gas reliquefaction system includes: a compressor compressing boil-off gas generated from liquefied gas stored in an on-board storage tank; a heat exchanger cooling the boil-off gas compressed in the compressor; a refrigerant circulation line in which a refrigerant supplied to the heat exchanger circulates; a temperature raising line extending from the storage tank to the compressor; and a heater provided to the temperature raising line, wherein the heater heats the boil-off gas to a suitable input temperature of the compressor.

Abstract: A display apparatus includes pixels. Each of the pixels includes a first node controller applying a data voltage to a first node, a second node controller shifting a voltage of a second node from a low level driving voltage to an on pulse voltage, a third node controller applying a reference voltage having an on level to a third node during a first period in one frame and applying the low level driving voltage to the third node during a second period, a driving transistor being on-duty-driven during the first period and off-duty-driven during the second period, and a light emitting device including an anode electrode connected to the second electrode of the driving transistor and a cathode electrode. The light emitting device emits light responsive to a constant current applied from the driving transistor during the first period and does not emit light during the second period.

Abstract: Disclosed herein are a pharmaceutical composition for prevention, alleviation, or treatment of any disease selected from the group consisting of type 2 diabetes mellitus, hyperinsulinemia, impaired glucose tolerance disorder, and insulin resistance disorder, wherein the pharmaceutical composition includes a GPR40 agonist and an SGLT2 inhibitor, the GPR40 agonist being a compound represented by Formula 1, a racemate of the compound, an enantiomer of the compound, a diastereomer of the compound, or a pharmaceutically acceptable salt of the compound, the racemate, the enantiomer or the diastereomer, a method of preparing the same, and a method of treating type 2 diabetes mellitus and the like using the same.

Abstract: A refrigerant charging system includes: a reliquefaction system reliquefying boil-off gas generated in a liquefied gas storage tank by compressing the boil-off gas and subjecting the compressed boil-off gas to heat exchange with refrigerant supplied to a heat exchanger while circulating along a refrigerant circulation line; a buffer tank storing utility N2 to be supplied to the ship; a booster compressor receiving the utility N2 from the buffer tank, compressing the received N2, and supplying the compressed N2 to the refrigerant circulation line; and a first load-up line along which the N2 is supplied from the buffer tank to the refrigerant circulation line without passing through the booster compressor. Upon initial charging in a non-operation state of the reliquefaction system, the refrigerant circulation line is charged with refrigerant by supplying the N2 from by a pressure differential between the refrigerant circulation line and the buffer tank.

Abstract: This invention relates to a highly functional graft copolymer and a method of preparing the same, and more particularly, to a highly functional graft copolymer including a main chain of a highly elastic ethylene-based terpolymer including, at a predetermined molar ratio, an ethylene unit, an ?-olefin unit having 6 to 12 carbon atoms, and at least one functional unit selected from the group consisting of divinylbenzene and p-methylstyrene, and a side chain of a polar polymer for imparting functionality, and to a method of preparing the highly functional graft copolymer by performing anionic polymerization after catalytic polymerization using a metallocene catalyst.

Abstract: The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment.

Abstract: The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment.

Abstract: The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment.

Abstract: The present invention relates to an ethylene-based terpolymer having high elasticity and a preparation method thereof, and more particularly, to a highly elastic, ethylene-based terpolymer, which comprises a specific molar ratio of a ethylene unit, a C6-12 ?-olefin unit and at least one functional unit selected from the group consisting of divinylbenzene and para-methylstyrene and to a method of preparing the highly elastic, ethylene-based terpolymer using a metallocene catalyst.

Abstract: The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment.

Abstract: The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment.

Abstract: The present invention relates to a self-adhesive protection film having improved release properties and a product attached with the same, and in particular, to a multilayered self-adhesive protection film having particularly enhanced release properties by comprising monodisperse beads in a carrier layer or the carrier layer being embo patterned, and to a product attached with the self-adhesive protection film.

Abstract: This invention relates to a highly functional graft copolymer and a method of preparing the same, and more particularly, to a highly functional graft copolymer including a main chain of a highly elastic ethylene-based terpolymer including, at a predetermined molar ratio, an ethylene unit, an ?-olefin unit having 6 to 12 carbon atoms, and at least one functional unit selected from the group consisting of divinylbenzene and p-methylstyrene, and a side chain of a polar polymer for imparting functionality, and to a method of preparing the highly functional graft copolymer by performing anionic polymerization after catalytic polymerization using a metallocene catalyst.

Abstract: The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment.